POSEDEL RHEA J sold $1.1M of AEHR (indirect holdings)

POSEDEL RHEA J (Director) sold 8,413 indirectly-held shares of AEHR TEST SYSTEMS (AEHR) at $130.00 ($1.09M total) on 2026-08-12.

Original reporting
SEC EDGAR · POSEDEL RHEA J
Published Aug 13, 2026, 9:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 9:45 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$AEHR
Neutral
medium confidence
Mentioned
$AEHR
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AEHRNeutralLow
01

Why it matters

The only new fact is the size, price, and timing of the director’s sale. It does not provide new information about AEHR’s business performance or outlook.

02

Market read

Traders may monitor for follow-on insider activity, but the disclosure alone is unlikely to drive a durable repricing without additional catalysts.

03

What to watch

The transaction is labeled indirect and no 10b5-1 plan is indicated; traders may want to check for other recent insider transactions or subsequent filings for context.

Relevance 6/10Novelty 5/10Timing: filed after-hours on 2026-08-13, covering a sale dated 2026-08-12

Background

The article is an SEC Form 4 insider transaction disclosure for AEHR, reported by a director via an indirect holding.

Company-level read

Ticker impact

$AEHRNeutralMedium confidence
Context

AEHR director Rhea J Pose del sold 8,413 shares at $130 on 2026-08-12, totaling about $1.09M, via an indirect holding.

Expected impact

Likely limited, short-lived sentiment impact unless follow-on selling or other disclosures emerge.

Evidence & confidence

The filing is a Form 4 open-market sale with no 10b5-1 plan stated, but it does not include new operating, guidance, or regulatory information.

Market effects

Minimal; insider-sale filings rarely reset sector expectations without accompanying company news.

None indicated.

None indicated.

Counterpoint

The sale may be routine liquidity management, especially since the filing does not cite any adverse company development.

Key entities

  • AEHR

    AEHR Test Systems, the company whose director transaction is disclosed.

  • POSEDEL RHEA J

    Director reporting an open-market sale of AEHR shares via an indirect holding.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AEHRHighAI 9/10

Aehr Test Systems (AEHR) (Q1 2027) Earnings Call Highlights: Record Revenue, Raised

Aehr Test Systems (AEHR) reported record Q1 2027 revenue of $33M and raised annual guidance to $150M. CEO Gayn Erickson highlighted a potential large burn-in opportunity, estimating $35M-$70M in revenue per million units shipped. The company expects sequential growth in remaining quarters, with Q4 potentially the highest. Management confirmed they are not supply-constrained and can ship more than guided. Silicon carbide revenue was about $10M in fiscal 2026, with expectations for growth in 2027.

$AEHRHighAI 9/10

AEHR Stock Surges After Massive AI-Driven Earnings Beat

Aehr Test Systems (AEHR) stock rose 26.6% after reporting Q1 FY27 revenue of $33M, up 300% year-over-year and 75% quarter-over-quarter. Adjusted EPS was $0.28, beating estimates. The company raised FY27 revenue guidance to $150M, citing strong demand for AI and power semiconductor testing.

$AEHRHighAI 9/10

Aehr Stock Jumps 16% After Bookings Hit $46.7 Million

Aehr Test Systems (AEHR) shares rose 16.38% premarket after its Q1 revenue tripled to $33.0M, beating estimates. The company raised its full-year outlook to $150M, citing strong bookings and backlog growth. CEO Gayn Erickson highlighted a major AI customer opportunity. According to GuruFocus, there are 6 warning signs with AEHR.

$AEHRHighAI 8/10

Why is Aehr Test Systems stock surging today?

Aehr Test Systems (AEHR) stock surged 18.8% in pre-market trading after reporting record Q1 2027 revenue of $33.0M, up 200% YoY, and raising full-year revenue outlook to $150M. Non-GAAP net income was $9.4M, or $0.28 per share, exceeding analyst estimates. The company cited strong demand for AI semiconductor test solutions and a book-to-bill ratio of 1.4.

$AEHRMed

Aehr stock jumps on beat and raise amid AI demand

Aehr Test Systems (AEHR) shares rose 15% after reporting Q1 revenue of $33M, up 200% YoY, and raising its FY2027 outlook to $150M. The company cited strong demand for its semiconductor testing systems used in AI chips. CEO Gayn Erickson noted a conservative approach to the revised target. Bookings were $46.7M with a book-to-bill ratio of 1.4.